Brokerages Expect Targacept Inc. (NASDAQ:CBIO) to Post ($0.48) Earnings Per Share
Targacept Inc. (NASDAQ:CBIO) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokers have set a one year consensus target price of $3.50 for the company and are predicting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also assigned Targacept an industry rank of 107 out of 265 based on the ratings given to related companies.
Several equities analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $3.50 target price on shares of Targacept in a report on Thursday. Rodman & Renshaw assumed coverage on Targacept in a report on Thursday, June 30th. They issued a “buy” rating and a $3.50 target price on the stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/brokerages-expect-targacept-inc-nasdaqcbio-to-post-0-48-earnings-per-share.html
Targacept (NASDAQ:CBIO) traded down 4.24% during trading on Friday, hitting $1.13. The company’s stock had a trading volume of 34,395 shares. The company has a 50-day moving average of $1.25 and a 200 day moving average of $1.44. The firm’s market cap is $13.37 million. Targacept has a one year low of $1.11 and a one year high of $6.04.
Targacept (NASDAQ:CBIO) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.11. Targacept had a negative net margin of 4,155.13% and a negative return on equity of 62.53%. On average, equities analysts forecast that Targacept will post ($1.40) earnings per share for the current year.
Targacept Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Targacept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Targacept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.